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The conserved CDC5 family of Myb-related proteins performs an
essential function in cell cycle control at G2yM. Although c-Myb and
many Myb-related proteins act as transcription factors, herein, we
implicate CDC5 proteins in pre-mRNA splicing. Mammalian CDC5
colocalizes with pre-mRNA splicing factors in the nuclei of mam-
malian cells, associates with core components of the splicing
machinery in nuclear extracts, and interacts with the spliceosome
throughout the splicing reaction in vitro. Furthermore, genetic
depletion of the homolog of CDC5 in Saccharomyces cerevisiae,
CEF1, blocks the first step of pre-mRNA processing in vivo. These
data provide evidence that eukaryotic cells require CDC5 proteins
for pre-mRNA splicing.
The Schizosaccharomyces pombe cdc5-120 mutant was isolatedin a screen for mutants defective in cell cycle progression (1).
At the restrictive temperature, cdc5-120 cells arrest growth in G2
(1, 2), indicating that cdc51 function is required for G2yM
progression. CDC5 has been conserved throughout evolution,
and related genes have been cloned from Saccharomyces cerevi-
siae (termed CEF1; ref. 3), Arabidopsis thaliana (4), Drosophila
melanogaster (3), Caenorhabditis elegans (3), Xenopus laevis (5),
and Homo sapiens (3, 6, 7). We conclude that these proteins are
conserved functionally, because D. melanogaster and human
CDC5 (hCDC5) complement the cdc5-120 mutant, S. cerevisiae
CEF1 is essential during G2yM in this evolutionarily distinct
yeast (3), and overexpression of dominant negative forms of
hCDC5 slows G2 progression in mammalian cells (8).
In their N termini, CDC5 proteins are highly related to the
DNA-binding domain of human c-Myb (2, 3, 9). Whereas human
c-Myb contains three Myb repeats, ’50-amino acid motifs with
characteristic spacing of tryptophan residues (9), CDC5 proteins
contain two Myb repeats (R1 and R2) followed by a Myb-like-
repeat (MLR3) that contains some, but not all, of the hallmarks
of a typical Myb repeat (3). Based on their homologies to c-Myb,
CDC5 proteins were hypothesized to carry out their essential
function in cell cycle control through transcriptional regulation,
a notion supported by the following observations: (i) the Myb
repeats of S. pombe cdc5p fused to glutathione S-transferase-
bound DNA cellulose (2); (ii) the Myb repeats of A. thaliana
cdc5p selected a specific DNA sequence in a cyclic amplification
and selection of targets protocol (4); and (iii) the C terminus of
hCDC5 fused to the GAL4-DNA binding domain activated
transcription in a reporter assay (8). To date, however, no
downstream transcriptional targets for any of the CDC5 proteins
have been identified.
hCDC5 was identified recently in a biochemical purification of
the mammalian spliceosome assembled in vitro (10), indicating
that CDC5 proteins may be involved in pre-mRNA splicing
rather than transcriptional regulation. Herein, we extend this
observation by showing that mammalian CDC5 colocalizes with
splicing factors in the nuclei of mammalian cells, coimmunopre-
cipitates with core components of the splicing machinery from
nuclear extracts, and interacts with the spliceosome throughout
the splicing reaction in vitro. Finally, we present evidence that
eukaryotic cells require the CDC5 family of proteins for pre-
mRNA splicing in vivo.
Materials and Methods
DNA manipulations were performed by using standard tech-
niques (11). Details of plasmid construction and oligonucleotide
sequences are available on request.
Mammalian Cell Culture Conditions and Flow Cytometric Analysis.
NIH 3T3 and HeLa cells were cultured in DMEM and 10%
(volyvol) bovine calf serum or 10% (volyvol) FBS, respectively.
TsBN2 cells (12) were cultured and shifted to the restrictive
temperature for 10 h as described (13). Asynchronously growing
subconfluent NIH 3T3 cells were rendered quiescent by incu-
bation for 24 h in DMEM containing 0.1% bovine calf serum.
For flow cytometric analysis, cells were trypsinized, collected by
centrifugation, and fixed overnight at 4°C in 70% (volyvol) ethyl
alcohol. The next day, cells were incubated for 30 min with 0.1
mgyml RNase and 0.05 mgyml propidium iodide in 50 mM
sodium citrate. Flow cytometric analysis was conducted with a
Becton Dickinson fluorescence-activated cell sorter (FACScan).
Generation of hCDC5 Polyclonal Antisera. The C-terminal 440 and
the N-terminal 363 amino acids of hCDC5 were produced
separately in Escherichia coli as hexahistidine fusion proteins and
used to generate polyclonal antisera in rabbits. Antisera were
affinity-purified against hCDC5C or hCDC5N as described (14).
Protein Lysates, Subcellular Fractionation, Production, and Immuno-
precipitation of hCDC5 in Vitro. Subconfluent NIH 3T3 and HeLa
cells were lysed in 13 SDS sample buffer [0.125 M TriszHCl, pH
6.8y10% (vol/vol) glyceroly2% (vol/vol) SDSy10% (vol/vol)
b-mercaptoethanol Bromophenol blue]. Lysates were heated to
95°C for 5 min and clarified before loading. Nuclear and
cytoplasmic fractions of cultured cells were prepared as de-
scribed (15). hCDC5 and 6XHisyMyc-tagged hCDC5 were
produced in vitro in the presence of TRAN35S-LABEL (ICN) by
using rabbit reticulocyte lysate (Promega). Nonidet P-40 buffer
(500 ml; ref. 16) was added to each 50-ml reaction, and the lysates
were clarified for 30 min at 4°C. Proteins were immunoprecipi-
tated with 3 ml of preimmune or immune hCDC5C antiserum or
5 mg of the anti-Myc (9E10) monoclonal antibody. For immu-
noprecipitations with 9E10, affinity-purified rabbit anti-mouse
secondary antibodies were added before addition of protein A
Sepharose (Amersham Pharmacia).
Immunoblotting. Proteins were separated by SDSyPAGE and
transferred to poly(vinylidene difluoride) membranes. Primary
antibodies were used at dilutions of 1:1,000 or 1:2,000 for
preimmune and immune hCDC5C antisera, respectively; 1:300
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for affinity-purified hCDC5C antiserum; and at 0.5 mgyml for
preimmune IgG or affinity-purified hCDC5N antiserum. Mono-
clonal anti-actin antibodies (Amersham Pharmacia) were used at
1:2,000. Peroxidase-conjugated goat anti-rabbit or sheep anti-
mouse secondary antibodies were used at 10,000-fold dilutions.
Reactive proteins were detected by using enhanced chemilumi-
nescence detection (Amersham Pharmacia).
Indirect Immunofluorescence. Subconfluent cells attached to cov-
erslips were fixed with 1:1 (volyvol) methanol:acetone for 5 min
at room temperature. Cells were blocked at 37°C with 3%
(volyvol) BSA, followed by incubation with 1:25 or 1:50 affinity-
purified hCDC5C antiserum. For colocalization studies, cells
were simultaneously incubated with 0.05 mgyml anti-SC35
monoclonal antibody (PharMingen). Fluorescein goat anti-
rabbit IgG conjugate (1:100 dilution of 2 mgyml stock; Molecular
Probes) and Texas Red goat anti-mouse IgG conjugate (1:100
dilution of 2 mgyml; Molecular Probes) were used to detect the
primary antibodies. DNA was visualized by incubating the cells
in 0.5 mgyml Hoechst 33258 (Sigma). Cells were photographed
through a Zeiss Axioskop microscope with 340 or 3100 objec-
tives and appropriate filters. Images were captured with a cooled
CCD camera (Optronics ZVS-47DEC, Goleta, CA). Confocal
microscopy and overlay analysis were performed on a Zeiss
LSM410 Confocal Laser Scanning Microscope with a 363
objective.
Transient Transfection of ClkySty Kinase in NIH 3T3 Cells. NIH 3T3
cells were transfected with a plasmid that constitutively expresses
N-terminally Myc-tagged mouse ClkySty (pECE-M-STY; ref.
17). Transfections were performed with Lipofectamine (Life
Technologies). After 24 h, cells were processed for indirect
immunofluorescence with 9E10 monoclonal antibody and affin-
ity-purified hCDC5C antiserum.
Immunoprecipitation of Small Nuclear RNAs (snRNAs), Small Nuclear
Ribonucleoproteins (snRNPs), and Spliceosomes. Immunoprecipita-
tions were carried out in IPP150 (10 mM TriszHCl, pH 8.0y150
mM KCly0.1% NP-40) buffer essentially as described (18).
Briefly, 20 ml of packed protein A Sepharose 4B fast f low resin
(Sigma) was precoated with 20 ml of hybridoma ascites contain-
ing monoclonal antibodies against maltose-binding protein
(AK105; ref. 48) or 40 mg of Sm Ab-1 (Clone Y12; Neomarkers,
Fremont, CA). Beads (20 ml) were also precoated with 2 ml of
either preimmune or immune hCDC5C antiserum. The beads
were then incubated for 1 h at 4°C with 25 ml of HeLa-cell
nuclear extract prepared as described below. snRNAs were
immunoprecipitated with 100 mg of agarose-linked 2,2,7-
trimethylguanosine (Ab-1) monoclonal antibodies (Oncogene
Research Products, Cambridge, MA).
In vitro splicing assays were carried out in HeLa-cell nuclear
extracts as described (19, 20). Capped and uniformly 32P-labeled
b-globin pre-mRNA substrate was produced in vitro from pSP64-
HbD6 (20, 21). b-Globin RNA species were visualized on 9%
polyacrylamide (29:1, acrylamideybisacrylamide)y8 M urea de-
naturing gels (20). Immunoprecipitation of spliceosomes was
carried out after 45 or 90 min of the reaction in IP100 (50 mM
TriszHCl, pH 7.6y100 mM KCly2 mM MgCl2y0.5 mM DTTy
0.05% NP-40) buffer essentially as described, with 15 ml of
protein A beads precoated with preimmune or immune anti-
hCDC5C or 30 ml of Y12 hybridoma ascites (monoclonal anti-
Sm; refs. 22 and 23).
S. cerevisiae Strains, Preparation of Total RNA, and Northern Blot
Analysis. KGY1120 and KGY1140 strains were grown under
permissive conditions and shifted to restrictive conditions ex-
actly as described (3). prp3–1(ts125; refs. 24 and 25), prp18 (ts503;
ref. 24), and cdc28–1N (26) temperature-sensitive strains were
grown in yeast extractypeptoneydextrose (27).
Total RNA was prepared from cells by extraction with hot
acidic phenol as described (28). Total RNA (20 mg per sample)
was electrophoresed on formaldehyde-agarose gels and capillary
blotted to a Duralon-UV membrane (Stratagene). After UV
crosslinking, blots were hybridized with labeled probes from
RP51a, DYN2, DBP2, or GLC7 ORFs or PCR fragments rep-
resenting the ACT1 or TUB3 intron sequences. Blots were
exposed to PhosphorImager screens and visualized by using MD
IMAGE QUANT (version 3.3) or IMAGE QUANT for Macintosh 1.1
(Molecular Dynamics).
Results
Characterization of hCDC5 Antisera. To facilitate studies of hCDC5,
rabbit polyclonal antibodies were raised against the C-terminal
440 amino acids (hCDC5C) or N-terminal 363 amino acids
(hCDC5N) of the protein. Crude and affinity-purified hCDC5C
and hCDC5N sera recognized specifically a single protein spe-
cies of 105 kDa from HeLa and NIH 3T3 whole-cell lysates (Fig.
1A; data not shown). To confirm that the 105-kDa proteins were
indeed hCDC5 and mouse CDC5 (mCDC5), two full-length
variants of hCDC5 differing only by the presence of a C-
terminally located 6XHisyMyc epitope were produced by in vitro
transcriptionytranslation. Both proteins were specifically immu-
noprecipitated by the hCDC5C antiserum (Fig. 1B), and hCDC5
produced in vitro comigrated with mCDC5 from NIH 3T3 cells
(Fig. 1C). Collectively, these data confirm that mammalian
CDC5 migrates at 105 kDa and that our polyclonal antibodies
recognize specifically mammalian CDC5 proteins.
Fig. 1. Characterization of hCDC5 antisera. (A) Immunoblots of whole-cell
protein extracts from NIH 3T3 (lanes 1, 2, and 5) and HeLa (lanes 3, 4, and 6–8)
cells probed with preimmune (lanes 1 and 3), immune (lanes 2 and 4), and
affinity-purified (lanes 5 and 6) antisera raised against the C terminus of
hCDC5 (hCDC5C), and preimmune IgG (lane 7) and affinity-purified antisera
(lane 8) raised against the N terminus of hCDC5 (hCDC5N). (B and C) Analysis
of hCDC5 produced in vitro. hCDC5 or 6XHisyMyc-tagged hCDC5 proteins
were produced in vitro in the presence (B) or absence (C) of TRAN35S-LABEL.
In B, total products of the reactions (lanes 1 and 2), preimmune (lane 3) or
anti-hCDC5C (lane 4) immunoprecipitates, and immunoprecipitates of the
6XHisyMyc-tagged hCDC5 with no primary antibody (lane 5) or 9E10 antibody
(lane 6) were resolved by SDSyPAGE. Proteins were detected by fluorography.
In C, an NIH 3T3 cell lysate (lane 1), hCDC5 produced in vitro (lane 2), and
6XHisyMyc-tagged hCDC5 produced in vitro (lane 3) were resolved by SDSy
PAGE and immunoblotted with anti-hCDC5C serum. In both B and C, asterisks
denote the 6XHisyMyc-tagged species of hCDC5. For all panels, numbers to the
left indicate molecular mass (in kDa).
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Subcellular Localization of CDC5. By indirect immunofluorescence,
endogenous mCDC5 protein was localized to the nuclei of NIH
3T3 cells in a punctate pattern, except during metaphase and
anaphase when mCDC5 became localized diffusely throughout
the cell (Fig. 2A). mCDC5 was excluded from phase-dark regions
of the nucleus presumed to be nucleoli. Cells in metaphase and
anaphase, identified by cellular and chromosomal morphology,
displayed a uniform distribution of mCDC5 with exclusion from
segregating chromosomes. In telophase cells, mCDC5 localized
exclusively to the reforming nucleus in a speckled pattern (Fig.
2A). Identical staining patterns were observed with affinity-
purified hCDC5N antibodies, by using formaldehyde rather than
methanol as fixative, in HeLa, CV-1, and COS-7 cell lines (data
not shown). Cells stained with preimmune serum or secondary
antibodies alone failed to produce fluorescent signals (data not
shown).
To rule out the possibility that a cytoplasmic pool of mCDC5
had gone undetected by indirect immunofluorescence, NIH 3T3
cells were fractionated biochemically into nuclear and cytoplas-
mic pools. In agreement with the indirect immunofluorescence
results, mCDC5 was detected in the nuclear but not the cyto-
plasmic fraction (Fig. 2C). Conversely, actin was detected in the
cytoplasmic but not the nuclear fraction, indicating that the
fractionation procedure had been successful (Fig. 2C).
It has been reported that exogenously expressed hCDC5 is
cytoplasmic after serum deprivation, and that, on serum stim-
ulation, hCDC5 translocates into the nucleus (6). To determine
whether the localization of endogenous CDC5 was altered by
serum conditions, indirect immunofluorescence was performed
on NIH 3T3 cells that had been deprived of serum for 24 h. A
significantly greater proportion (95%) of serum-deprived cells
contained a 1 N content of DNA when compared with asyn-
chronously growing serum-fed cells (63%). Thus, these cells had
been appropriately serum starved. Serum-deprived NIH 3T3
cells displayed a punctate, nuclear staining pattern of CDC5,
indistinguishable from that seen in asynchronously growing cells
(Fig. 2B). The nuclear localization of CDC5 was again confirmed
by biochemical fractionation (Fig. 2C). CDC5 was also detected
in the nucleus of serum-deprived COS-7 and CV-1 cells under
the conditions used previously (data not shown; ref. 6). The
pattern of punctate staining was not altered in these cells after
serum addition (data not shown).
CDC5 Localizes to the Nuclear Speckles. The nuclear, punctate
distribution of CDC5 resembled that of factors involved in
pre-mRNA splicing, which are concentrated into ‘‘nuclear speck-
les’’ (for review see ref. 29). To determine whether CDC5
localized to nuclear speckles, NIH 3T3 cells were costained for
a non-snRNP component of the spliceosome and a marker of the
nuclear speckle (SC35; refs. 30 and 31) by using an anti-SC35
monoclonal antibody and for mCDC5 by using affinity-purified
hCDC5C antiserum. In all interphase nuclei observed, the
distribution of brightly staining mCDC5 foci mirrored the SC35
staining pattern (Fig. 3A), although the more diffuse pool of
mCDC5 did not colocalize with SC35. Colocalization of CDC5
with SC35 was also observed in asynchronously growing and
serum-deprived NIH 3T3, CV-1, and COS-7 cells (data not
shown). No staining was observed when the secondary antibod-
ies used to detect CDC5 antibodies and the SC35 monoclonal
antibody were interchanged (data not shown).
During metaphase and early anaphase, SC35 staining is
uniform throughout the cell body (32). In late anaphase and
telophase, SC35 antigens reassociate into speckles that appear in
both the cytoplasm and reforming telophase nuclei (Fig. 3A; 32).
In contrast, during telophase, mCDC5 was localized completely
to the reforming nuclei in foci that colocalized with the nuclear
subset of SC35 speckles (Fig. 3A). These data indicate that CDC5
and SC35 translocate into the nucleus with different kinetics
after chromosome segregation.
We reasoned that, if CDC5 proteins are indeed bona fide
components of the nuclear speckles, then treatments that alter
the spatial distribution of speckle proteins (for review see ref. 29)
should similarly modulate the subnuclear localization of mam-
malian CDC5. In particular, tsBN2 cells (12) reorganize splicing
factors into 4–10 large clusters at the restrictive temperature
(13). To determine whether the CDC5 distribution is similarly
reorganized, tsBN2 cells were shifted to 39.5°C for 10 h and
costained for SC35 and CDC5. At 32.5°C, SC35 and CDC5
colocalized and displayed a normal speckled distribution (data
not shown). In contrast, at 39.5°C, SC35 antigens and CDC5
reorganized into abnormally large clusters (Fig. 3B), indicating
that CDC5 behaves like other speckle-associated proteins under
these conditions.
To disperse nuclear speckles, we overexpressed the SR protein
kinase ClkySty in NIH 3T3 cells (33). A plasmid expressing
Myc-tagged ClkySty under control of the cytomegalovirus pro-
moter was transfected into NIH 3T3 cells, and 24 h later, cells
were fixed and costained for the Myc epitope, which allowed the
identification of transfected cells and mCDC5. As described
previously, transfected ClkySty localized diffusely throughout
Fig. 2. Subcellular localization of CDC5 throughout the cell cycle and in
serum-deprived cells. (A) Phase contrast (a, d, g, and j) and fluorescence
micrographs of NIH 3T3 cells stained with Hoechst (b, e, h, and k) and
affinity-purified hCDC5C antiserum (c, f, i, and l). Cells in interphase (a–c),
metaphase (d–f ), anaphase (g–h), and telophase (j–l) are shown. (B) Localiza-
tion of CDC5 in serum-deprived NIH 3T3 cells. Phase contrast (a) and fluores-
cence micrographs of NIH 3T3 cells deprived of serum for 24 h and stained with
Hoechst (b) and affinity-purified hCDC5C antiserum (c). (C) Localization of
CDC5 in nuclear and cytoplasmic fractions of asynchronously growing and
serum-deprived NIH 3T3 cells. Equivalent amounts of nuclear and cytoplasmic
fractions prepared from asynchronously growing NIH 3T3 cells or cells that
were deprived of serum for 24 h were analyzed by immunoblotting by using
either hCDC5C antiserum or a monoclonal anti-actin antibody. (Bars 5 10 mm.)








the nucleus (33). In transfected cells, mCDC5 was significantly
more dispersed compared with untransfected cells (Fig. 3C).
These data indicate that CDC5 is a bona fide component of the
nuclear speckles.
hCDC5 Associates with Core Components of the Splicing Machinery
and the Spliceosome in Vitro. The observation that CDC5 colo-
calized with pre-mRNA splicing factors raised the possibility that
CDC5 associates in vivo with components of the pre-mRNA
splicing machinery. Indeed, hCDC5 was found in both anti-Sm
and anti-m3G immunoprecipitates prepared from HeLa-cell
nuclear extracts (Fig. 4A), and approximately 20% of total
hCDC5 in the extract could be immunoprecipitated by using
anti-m3G antibodies (data not shown). We next investigated
whether hCDC5 antiserum could immunoprecipitate spliceo-
somes from in vitro splicing reactions. After incubation of a
nuclear splicing extract containing 32P-labeled b-globin pre-
mRNA for 45 or 90 min, both anti-Sm (Y12 hybridoma ascites;
ref. 23) and anti-CDC5 but not preimmune antibodies immu-
noprecipitated approximately 5% of b-globin pre-mRNA, the
lariat intermediate, and mature b-globin mRNA (Fig. 4B). By
quantitating the maximal amount of b-globin immunoprecipi-
tated by anti-hCDC5 serum relative to that of anti-Sm antibod-
ies, we determined that hCDC5 was associated with approxi-
mately one-third of the spliceosomes in vitro (data not shown).
S. cerevisiae Cells Lacking the Ortholog of S. pombe cdc51, CEF1, Are
Defective in pre-mRNA Splicing. Finally, we wanted to test whether
eukaryotic cells require Cdc5 proteins for pre-mRNA splicing in
vivo. We decided to analyze S. cerevisiae cells genetically de-
pleted of CEF1 for pre-mRNA splicing defects. A S. cerevisiae
strain (KGY1120) lacking endogenous CEF1 and harboring
plasmid-borne CEF1 cDNA under the control of the GAL1
promoter arrests growth during G2yM after 10 h of CEF1
repression (3). We looked for accumulation of immature forms
of several intron-containing genes by Northern blot analysis over
a 10-h time course of CEF1 repression. Cef1p is detectable until
Fig. 3. CDC5 is a component of the nuclear speckles. (A) NIH 3T3 cells were
costained with affinity-purified hCDC5C antiserum and a monoclonal anti-
body against SC35. Fluorescein and Texas Red-conjugated secondary antibod-
ies were used to detect the distribution of CDC5 (a, d, and g) and SC35 (b, e,
and h), respectively. Confocal images of cells in interphase (a–f ) and telophase
(g–i) were obtained and merged (c, f, and i). Regions of colocalization are
yellow in merged images. (B) Asynchronously growing tsBN2 cells were shifted
to the nonpermissive temperature and costained with affinity-purified
hCDC5C antiserum (a) and a monoclonal antibody to SC35 (b). The confocal
images were merged in c. (C) Myc-tagged ClkySty kinase was transfected into
NIH 3T3 cells. Phase contrast images (a) of cells costained with anti-Myc
epitope monoclonal antibodies (9E10; b) and affinity-purified hCDC5C anti-
serum (c) at 24 h after transfection. (Bars 5 10 mm.)
Fig. 4. hCDC5 interacts with core components of the splicing machinery and
the spliceosome in vitro. (A) Immunoprecipitations (IP) from a nuclear splicing
extract were performed with three monoclonal antibodies [irrelevant mono-
clonal antibody (AK105), anti-Sm (Y12), and anti-snRNA cap (anti-trimethyl-
guanosine; a-m3G)] and preimmune (PI) or immune (I) hCDC5C antiserum.
Immunoprecipitates were blotted with hCDC5C antiserum. (B) hCDC5 or Sm
proteins were immunoprecipitated from an in vitro splicing reaction contain-
ing labeled b-globin pre-mRNA at 45 or 90 min after addition of pre-mRNA,
and 1y10 of the total reactions were run as standards. The identities of the
RNA species are indicated to the left.
13792 u www.pnas.org Burns et al.
8 h of repression (data not shown). KGY1120 mRNA was
compared with that isolated from four control strains: (i)
KGY1140 (3), a strain isogenic to KGY1120 but containing
endogenous CEF1 as a control for growth conditions; (ii) prp3–1,
a positive control for a defect in the first step of splicing (24); (iii)
prp18 (ts503), a positive control for a defect in the second step
of splicing (24); and (iv) cdc28-1N, a G2 arrest (26) control to
ensure that any observed splicing defects were not secondary to
cell cycle arrest.
Initially, we assayed two intron-containing transcripts that are
routinely used to analyze splicing defects in prp mutants ACT1
and RP51a (24). In KGY1120 cells under CEF1 repression,
intron-containing forms of both transcripts steadily accumulated
and peaked by 10 h (Fig. 5A). At this time, the abundance of each
unspliced transcript was comparable to that observed in prp3–1
cells (Fig. 5A). Next, we assayed two transcripts with unusual
intron properties, DYN2, one of two transcripts in S. cerevisiae
that contains two introns, and DBP2, the transcript with the
largest intron in the S. cerevisiae genome (34). Similar to ACT1
and RP51a, DYN2 and DBP2 unspliced transcripts accumulated
progressively after CEF1 repression (Fig. 5B). At 10 h, DYN2 and
DBP2 pre-mRNAs had roughly equivalent or greater abundance,
respectively, than the same pre-mRNAs in the prp3–1 mutant.
Furthermore, the levels of mature DYN2 decreased dramatically
throughout the time course. Finally, we analyzed two intron-
containing transcripts, GLC7 and TUB3, that encode proteins
required for mitotic progression (35–38). Unspliced GLC7 ac-
cumulated throughout the time course of CEF1 repression (Fig.
5C). Similarly, intron-containing transcripts of the a-tubulin
encoding TUB3 (36) increased throughout the time course (Fig.
5C). Taken together, these data indicate that CEF1 is essential
for pre-mRNA splicing in vivo.
Discussion
CDC5 proteins are essential for G2yM progression in S. pombe
(2), S. cerevisiae (3), and likely in higher eukaryotic cells (8).
Despite a well documented role for these proteins in cell cycle
progression, their biochemical function or functions are un-
known. Consistent with CDC5 proteins containing homology to
the well characterized DNA-binding factor and transcriptional
activator c-Myb, we and others have demonstrated that the Myb
domains of CDC5 proteins display affinity for double-stranded
DNA (2, 4). Furthermore, the C terminus of hCDC5 fused to the
GAL4-DNA-binding domain activated transcription in a tran-
scriptional reporter assay (8). Beyond these properties, however,
there is little evidence to suggest that CDC5 proteins function as
transcription factors in vivo.
In fact, a recent report that hCDC5 associates with the
spliceosome assembled in vitro (10) raised the possibility that
CDC5 proteins are involved in pre-mRNA splicing. Our data
confirm and extend this idea and show that mammalian CDC5
colocalizes with pre-mRNA splicing factors in mammalian cells,
associates with core components of the splicing machinery in
nuclear extracts, and interacts with the spliceosome throughout
the splicing reaction in vitro. We have also shown that genetic
depletion of S. cerevisiae CEF1 blocks pre-mRNA splicing in
vivo. These data provide evidence that eukaryotic cells require
CDC5 proteins for pre-mRNA splicing. While an earlier version
of this report was under review, similar conclusions were reached
regarding the requirement for Cef1p in pre-mRNA splicing in
vivo (39).
Although our data, as well as those of others (10, 39), are
consistent with the notion that CDC5 proteins function directly
in pre-mRNA splicing, we are unable to draw such a strong
conclusion. To do so, it would have to be shown that immu-
nodepletion of hCDC5 abrogated pre-mRNA splicing in vitro.
Subsequent readdition of hCDC5 should then restore pre-
mRNA splicing to the depleted extract. Although we were able
to remove the majority of hCDC5 from a HeLa-cell S100 extract
by immunodepletion, ’5% of the protein remained in the
extract, and the depleted extract spliced b-globin (data not
shown). We did observe, however, that preincubation of S100
extract with affinity-purified hCDC5N antibodies inhibited the
splicing reaction, whereas equivalent amounts of control anti-
bodies had no effect on the reaction (data not shown). That
antibodies to hCDC5 inhibited pre-mRNA splicing in vitro
corroborates the finding that antibodies to Cef1p inhibit pre-
mRNA splicing in S. cerevisiae extracts (39). Thus, further
investigations into hCDC5yCef1p function are likely to reveal
that these proteins play a direct role in the process of pre-mRNA
splicing.
We have observed that mammalian CDC5 localized to the
nucleus regardless of serum conditions. This result contrasts with
a previous report indicating that epitope-tagged and overex-
pressed hCDC5 localized exclusively to the cytoplasm in serum-
deprived cells (6, 8). There are at least two simple explanations
for this discrepancy. First, whereas the previous study examined
the localization of epitope-tagged cytomegalovirus-expressed
hCDC5, we have examined the localization of endogenous
CDC5. Second, both of these studies observed the localization of
CDC5 at steady state. Because some splicing factors shuttle
Fig. 5. S. cerevisiae cells lacking CEF1 are defective in pre-mRNA splicing.
Strains containing (CEF1) or lacking the endogenous copy of CEF1 (cef1D)
harboring plasmid-borne CEF1 cDNA under the control of the GAL1 promoter
were maintained in synthetic medium containing raffinose and galactose.
CEF1 expression was repressed by shifting the cells to synthetic medium
containing glucose (SD). Aliquots of cells were collected at the number of
hours indicated after the shift into SD. Total RNA was also purified from
temperature-sensitive mutants prp3–1, prp18 (ts503), and cdc28–1N shifted to
the restrictive temperature (35.5°C) for the number of hours indicated. Total
RNA (20 mg) was electrophoresed and blotted. (A) Northern blots probed with
the ACT1 intron sequence or the RP51a ORF. (B) Northern blots probed with
the labeled ORFs for DYN2 and DBP2. (C) Northern blots probed with the GLC7
ORF or TUB3 intron sequence. PC, precursor mRNA; M, mature mRNA.








continuously between the cytoplasm and the nucleus (40), the
difference between our observations may result from nucleocy-
toplasmic shuttling of mammalian CDC5. Perhaps serum star-
vation causes cytoplasmic retention of overexpressed hCDC5,
thereby explaining the observations reported in the previous
study.
Recent data call attention to the idea that pre-mRNA splicing
and cell cycle control are linked (reviewed in ref. 41). As
examples, most S. pombe prp mutants display cell cycle pheno-
types (42, 43); S. pombe cdc281, a putative RNA helicase, is
required for both pre-mRNA splicing and G2yM progression
(44); and cyclin E associates with and phosphorylates protein
components of the U2 snRNP (45). Several hypotheses have
been formulated to explain how a protein would function
simultaneously in cell cycle control and pre-mRNA splicing (for
review see ref. 41). One model predicts that a block in pre-
mRNA splicing depletes a transcript or transcripts necessary for
cell cycle progression. Indeed, it has been suggested that the
mitotic arrest of S. cerevisiae prp22 mutants results from a failure
to splice the mRNAs for TUB1 and TUB3 (46). Because we have
found that unprocessed TUB3 transcripts accumulate in cells
lacking CEF1, these cells might also arrest during G2yM (3)
because of a deficiency in a-tubulin protein.
Because precursor mRNAs were the most abundant species to
accumulate in cells lacking Cef1p, it is likely that CDC5 proteins
are required for the first biochemical step of pre-mRNA splicing.
Notably, genetic depletion of CEF1 did not affect the abundance
of several intronless transcripts, indicating that CEF1 function is
not globally required for mRNA production (3). Because the
function of S. pombe cdc51 is structurally and functionally
conserved in eukaryotes (3), these data are consistent with the
notion that all eukaryotic cells require CDC5 proteins for
pre-mRNA processing. Consistent with this hypothesis, we have
shown recently that S. pombe cdc5p is also required for pre-
mRNA splicing in vivo and associates with a snRNP-containing
complex (47). The CDC5 family of proteins represents a con-
served subfamily of Myb-related proteins necessary for pre-
mRNA splicing.
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